Shionogi backs Celaid’s Series B as CLD-001 nears U.S. push

Celaid Therapeutics has closed the second tranche of its Series B round, bringing in Shionogi & Co. as its first named investor. The Tokyo-based biotech declined to disclose the size of the tranche or the total raised, but the participation of a major pharmaceutical company could suggest interest in its lead candidate, CLD-001, as it advances toward U.S. development.

The undisclosed amount is notable in itself. Earlier coverage of the round did not include investor names, leaving the market to assess the round’s momentum based on limited details. Now, Shionogi’s emergence, given its history of biotech investments, could point to a deeper relationship.

The Manila Times reported that participating investors cited CLD-001’s development progress as a factor in their decision, though specifics remain scarce. The involvement of pharmaceutical companies in the round might imply a program of interest, though Celaid has not shared further details. This aligns with a broader trend: biotechs securing Series B funding often do so on the strength of a lead asset, particularly when larger players show engagement. Earlier this month, we noted that biotechs with partnerships from major firms were raising significant sums—Celaid’s round, though smaller, may follow a similar dynamic.

The next steps for Celaid remain unclear. The company’s decision to keep the round’s size under wraps could reflect a cautious approach, or it may indicate a modest tranche with Shionogi’s participation serving as validation. Either way, the lack of disclosure leaves open questions about the funding’s scale and intended use.

For now, the focus will likely remain on CLD-001’s development. If Celaid provides updates—whether through regulatory filings, trial progress, or additional partnerships—it could attract further attention. Until then, the Series B’s second tranche serves as a signal that pharmaceutical players may see potential in the pipeline, even if the full picture isn’t yet visible.

Sources: manilatimes.net